Published in Mod Pathol on February 01, 2006
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A (2007) 5.24
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res (2007) 4.41
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80
Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev (2013) 3.63
How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst (2014) 3.43
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A (2007) 2.85
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest (2007) 2.71
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer (2009) 2.60
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res (2009) 2.59
The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) (2010) 2.57
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature (2017) 2.54
Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat (2010) 2.49
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res (2009) 2.37
A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One (2009) 2.29
Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res (2009) 2.23
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res (2007) 2.12
Mammary development meets cancer genomics. Nat Med (2009) 2.04
Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A (2011) 2.01
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A (2009) 2.01
Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev (2009) 2.00
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest (2010) 2.00
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol (2011) 1.97
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res (2008) 1.94
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med (2012) 1.85
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol (2014) 1.74
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
MYC and Breast Cancer. Genes Cancer (2010) 1.66
Triple-negative breast cancer. Breast Cancer Res (2010) 1.65
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis (2010) 1.64
African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer (2010) 1.62
Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol (2009) 1.62
DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer (2008) 1.60
Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res (2007) 1.58
Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest (2014) 1.58
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res (2010) 1.56
Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol (2010) 1.55
Do 'basal-like' breast cancers really exist? Nat Rev Cancer (2008) 1.55
Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer (2008) 1.55
Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest (2010) 1.52
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer (2010) 1.52
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med (2007) 1.48
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer (2011) 1.48
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst (2011) 1.45
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat (2008) 1.44
The histological diagnosis of metastases to the breast from extramammary malignancies. J Clin Pathol (2007) 1.44
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer (2008) 1.38
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res (2011) 1.37
Molecular characterization of human breast tumor vascular cells. Am J Pathol (2008) 1.32
Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer (2007) 1.30
TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol (2010) 1.27
Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol (2009) 1.24
Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol (2010) 1.24
Demystifying basal-like breast carcinomas. J Clin Pathol (2007) 1.22
Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol (2006) 1.20
NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One (2011) 1.19
The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol Endocrinol (2009) 1.17
Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res (2011) 1.17
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res (2012) 1.16
Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. Exp Hematol Oncol (2013) 1.15
Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control (2011) 1.15
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis. Front Oncol (2015) 1.15
Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol (2009) 1.14
P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch (2006) 1.13
Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol (2010) 1.12
TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells. Breast Cancer Res (2008) 1.12
Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol (2013) 1.10
The origin of breast tumor heterogeneity. Oncogene (2015) 1.09
Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin Cancer Res (2012) 1.09
P-cadherin expression in breast cancer: a review. Breast Cancer Res (2007) 1.09
FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling. Oncogene (2012) 1.08
Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer. Int J Oncol (2013) 1.08
The TRAIL to targeted therapy of breast cancer. Adv Cancer Res (2009) 1.08
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res (2013) 1.08
Treatment options for patients with triple-negative breast cancer. J Hematol Oncol (2010) 1.07
A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas. Diagn Pathol (2012) 1.04
Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. Neoplasia (2008) 1.03
Tumour cell invasion: an emerging role for basal epithelial cell extrusion. Nat Rev Cancer (2014) 1.03
Triple-negative breast cancers: an updated review on treatment options. Curr Oncol (2011) 1.03
The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis. BMC Cancer (2008) 1.02
The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology (2011) 1.02
The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol (2016) 1.02
Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch (2008) 1.02
p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. Oncogene (2015) 1.02
RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. Mol Cell Proteomics (2011) 1.01
Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer. Onco Targets Ther (2013) 1.01
Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PLoS One (2012) 1.01
Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res (2008) 1.01
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
A custom microarray platform for analysis of microRNA gene expression. Nat Methods (2004) 9.44
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2008) 7.65
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res (2008) 7.39
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Deconstructing the molecular portraits of breast cancer. Mol Oncol (2010) 5.37
Adjustment of systematic microarray data biases. Bioinformatics (2004) 5.22
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell (2004) 3.91
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Common markers of proliferation. Nat Rev Cancer (2006) 3.85
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Molecular portraits and the family tree of cancer. Nat Genet (2002) 3.28
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet (2006) 3.19
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer (2007) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol (2007) 2.99
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res (2009) 2.84
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Statistical modeling for selecting housekeeper genes. Genome Biol (2004) 2.73
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
Gene expression patterns associated with p53 status in breast cancer. BMC Cancer (2006) 2.61
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 2.45
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38
Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res (2002) 2.33
A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One (2009) 2.29
RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res (2002) 2.25